The CAAP1 Knockout HAP1 Polyclonal Cells product comprises a polyclonal population of HAP1 cells in which the CAAP1 gene has been disrupted via CRISPR/Cas9-mediated genome editing, generating a heterogeneous loss-of-function pool. This polyclonal knockout format provides a versatile tool for studying CAAP1-dependent apoptosis regulation without the clonal biases inherent in single-cell-derived lines, allowing researchers to assess gene function across a diverse edited cell population.
HAP1 is a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia line. Its haploid karyotype simplifies genetic manipulation and phenotypic screening, as most genes are present in a single copy, facilitating clear genotype?Cphenotype correlations. Widely adopted for functional genomics, chemical screening, and cancer cell biology, HAP1 cells offer a robust platform for dissecting signaling pathways and drug responses in a hematologic malignancy context.
CAAP1 encodes a mitochondrial protein that functions as a negative regulator of the intrinsic apoptotic pathway. It directly binds and inhibits caspase-12, thereby blocking the activation of downstream effector caspases such as caspase-9 and caspase-3 and preventing cytochrome c release from mitochondria. Transcriptionally regulated by TP53 in response to genotoxic stress, CAAP1 is a p53 target gene that promotes cell survival. Additionally, CAAP1 activity intersects with PI3K/AKT survival signaling and NF-??B pathways, both frequently dysregulated in cancer. Key interacting factors include caspase-12 and mitochondrial membrane proteins, positioning CAAP1 at a critical node between pro-apoptotic (e.g., Bax, cytochrome c) and anti-apoptotic (e.g., Bcl-2) machinery.
In the HAP1 model, disruption of CAAP1 eliminates a key anti-apoptotic restraint, sensitizing cells to intrinsic apoptosis stimuli. This is particularly relevant for studying chemoresistance in leukemia, where CAAP1 overexpression often correlates with drug-refractory disease. The near-haploid background ensures that even heterozygous edits can produce pronounced phenotypes, while the polyclonal nature allows assessment of population-level responses, mimicking heterogeneous tumor cell behavior. Researchers can thus probe how loss of CAAP1 reshapes apoptotic signaling and alters sensitivity to chemotherapeutic agents.
This knockout product supports a wide range of assays to interrogate apoptosis and drug resistance mechanisms. Applications include western blotting for cleaved caspase-3 and PARP, RT-qPCR for CAAP1 and downstream targets, cell viability (MTT) and apoptosis (Annexin V/PI) assays, drug sensitivity profiling, flow cytometric measurement of mitochondrial membrane potential (JC-1 staining), and co-immunoprecipitation to validate caspase-12 interaction. It is also suited for high-throughput genetic screens and functional studies of p53-regulated apoptosis. For detailed technical support and ordering information, please contact Ascent Research.
